Analysis
DeepSeek is reportedly in talks to raise $1.5 billion in private funding as a deliberate step toward an eventual IPO, according to TechCrunch reporting published July 14. The move would make DeepSeek the most prominent Chinese AI lab to pursue a full public-listing path, arriving just weeks after Goldman Sachs research named DeepSeek one of its three preferred Chinese AI models -- alongside Zhipu and ByteDance -- ranking it ahead of larger names like Alibaba and Tencent specifically on speed-to-market and benchmark performance.
The sequencing here closely mirrors the playbook both Anthropic and OpenAI have followed toward their own public-listing processes: a large late-stage private round designed to set a clean valuation anchor before public price discovery, rather than jumping straight from private funding to a public filing. That convergence in strategy is notable given how differently US and Chinese frontier labs otherwise operate -- different capital markets, different regulatory regimes, and vastly different geopolitical scrutiny around export controls and data governance.
The competitive backdrop matters: DeepSeek has spent much of the past two years establishing itself as a genuine frontier-capability competitor to OpenAI and Anthropic on a fraction of the reported training cost, a reputation that's made it one of the most closely watched labs globally regardless of the geopolitical friction around Chinese AI companies accessing advanced chips. Its potential IPO would arrive as Zhipu, the only currently publicly-traded name among Goldman's three preferred Chinese models, provides an early read on how public markets price this cohort.
For global investors, a DeepSeek IPO would be the clearest test yet of whether Western and Hong Kong public markets are willing to underwrite a Chinese frontier-model lab at a valuation in the same conversation as Anthropic's roughly $965 billion private mark or OpenAI's own pre-IPO valuation, given the additional layer of export-control and geopolitical risk that doesn't apply to US-based labs.
The bear case: a Chinese AI lab pursuing a Western or Hong Kong listing faces meaningfully more geopolitical and regulatory uncertainty than a comparable US lab, including potential restrictions on which investors can participate and ongoing US export-control scrutiny that could affect DeepSeek's access to advanced compute regardless of its public-market status. What to watch next: which exchange DeepSeek ultimately targets for a listing, and whether the $1.5 billion raise closes at a valuation that gives a clean read on how the market is pricing DeepSeek relative to Zhipu's existing public trading.
